ACOT8

Across TCGA pan-cancer cohorts, ACOT8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACOT8 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACOT8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACOT8 expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where ACOT8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.612	0.865	.001	46	view →
HNSC	DFS	Tertile	III,IV	0.188	0.895	.006	30	view →
LUAD	DFS	Median	All	0.642	0.950	.004	24	view →
CCRCC	OS	Median	III,IV	0.640	0.931	.001	18	view →
LSCC	DFS	Tertile	All	0.560	1.000	.004	14	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACOT8–PDAC (DFS)

Open the PDAC breakdown →